Hs 746T / Hs 746T-luc Orthotopic Mouse Model Service for Gastric Cancer

The Hs 746T / Hs 746T-luc orthotopic mouse model brings a MET-driven human gastric adenocarcinoma into its native anatomical context, recreating organ-specific stromal interactions, locoregional invasion, and abdominal metastatic patterns that flank xenografts cannot reproduce. Alfa Cytology supports this model end to end as a preclinical service — from authenticated Hs 746T culture, STR profiling, and mycoplasma testing to luciferase line handling, subserosal gastric implantation in immunodeficient mice, serial in vivo bioluminescence imaging, dosing, and metastasis-focused histopathological endpoints.

Overview of Hs 746T / Hs 746T-luc Orthotopic Mouse Model for Gastric Cancer

Hs 746T is a hypertriploid human gastric adenocarcinoma cell line originally isolated from the pleural effusion of a 74-year-old male patient and distributed by ATCC as HTB-135. Its defining molecular trait is high-level MET gene amplification, which produces constitutive MET tyrosine kinase activation and renders the line dependent on HGF/MET signaling — a property that has made Hs 746T one of the most frequently cited gastric cancer models for evaluating c-Met inhibitors and multi-kinase strategies. Carrying TP53 and additional mutations, the line grows rapidly as an adherent epithelial culture and forms aggressive tumors in immunocompromised mice, including athymic nude, SCID, and NOD/SCID strains.

Fig 1. Magnetic resonance imaging of an Hs746T orthotopic gastric cancer model established by direct gastric-wall implantation, demonstrating diffuse tumor growth along the stomach wall characteristic of mesenchymal-type gastric cancer. (Jang, Eunji, et al., 2023)

In orthotopic applications, Hs 746T cells are implanted into the subserosal layer of the gastric wall, where they establish focal primary tumors embedded in the authentic peritoneal and gastric microenvironment. The luciferase-tagged counterpart, Hs 746T-luc, enables whole-body and ex vivo bioluminescence imaging after D-luciferin administration, so tumor initiation, local expansion, and spread to regional lymph nodes, peritoneum, liver, and lung can be followed quantitatively over time. Because imaging signal scales with viable tumor mass and occult deposits light up before they become palpable, the Hs 746T-luc orthotopic model supports time-resolved efficacy readouts, combination regimen benchmarking, and mechanistic studies of MET-pathway blockade within a human tumor context.

Cell Line Information: Hs 746T / Hs 746T-luc

Hs 746T is a well-characterized human gastric adenocarcinoma line with a hypertriploid karyotype and a MET-amplified, MET-addicted phenotype. The Hs 746T-luc variant carries a stably integrated firefly luciferase reporter, enabling sensitive optical tracking of tumor burden in vivo. Key attributes are summarized below.

Our Services

For teams working on MET-directed programs, model quality directly determines how interpretable the efficacy signal will be. Alfa Cytology maintains authenticated Hs 746T master stocks, applies STR verification and routine mycoplasma screening, and pairs this molecular rigor with practiced subserosal implantation technique so that orthotopic tumors initiate cleanly and imaging baselines stay comparable across cohorts. From feasibility assessments through full combination-therapy studies with metastasis staging, Alfa Cytology delivers an integrated preclinical package with transparent milestones and responsive scientific support at every step.

Workflow of Hs 746T / Hs 746T-luc Orthotopic Mouse Model Construction

Establishing an Hs 746T-luc orthotopic gastric cancer study links three disciplines — cell line stewardship, microsurgery, and optical imaging — into one traceable process. The workflow below describes the standard sequence, with defined controls at each handoff point.

1. Line authentication and reporter confirmation: Hs 746T / Hs 746T-luc stocks are verified by STR profiling, tested for mycoplasma, and checked for strong, homogeneous luciferase expression by in vitro luminescence assay.
2. Expansion and inoculum preparation: Cells are expanded in vitro in antibiotic-supplemented complete medium, harvested at controlled confluency, and prepared at the target concentration (for example, 1×10⁶ to 5×10⁶ viable cells in a minimal-volume PBS or Matrigel-containing suspension).
3. Recipient preparation: Immunodeficient mice (nude, SCID, or NSG, per study design) are acclimatized, grouped by body weight, and readied in a sterile surgical field with anesthesia and perioperative analgesia.
4. Orthotopic implantation: Following a small abdominal incision, the stomach is exteriorized and the cell suspension is delivered slowly into the subserosa of the gastric body using a fine-gauge needle; correct subserosal positioning is confirmed visually before the abdomen is closed in layers.
5. Recovery and baseline imaging: Animals recover under thermal and clinical monitoring, and baseline whole-body bioluminescence is recorded after D-luciferin administration to verify engraftment and establish starting photon flux.
6. Scheduled imaging and treatment execution: Photon flux is measured at defined intervals together with body weight and general condition; once tumors establish, cohorts are randomized by signal intensity and dosing begins according to the study plan.
7. Endpoint workup and analysis: At termination, primary gastric tumors are excised and weighed, abdominal organs and lymph nodes are systematically surveyed, ex vivo imaging localizes metastatic deposits, and tissues are fixed or frozen for histopathology and biomarker analysis.

Fig 2. Hs 746T / Hs 746T-luc orthotopic mouse model construction workflow.

Case Study-Hs 746T / Hs 746T-luc Orthotopic Mouse Model Development

Alfa Cytology has run preclinical programs on the Hs 746T orthotopic platform for clients advancing kinase-directed and combination strategies against gastric cancer. In these engagements, serial bioluminescence imaging captured treatment-induced changes in primary tumor burden over time, while end-of-study necropsies documented tumor weights and the distribution of abdominal metastases, with histopathology confirming lesion identity. Where programs required it, excised tissue was additionally processed for pathway-marker analysis to connect in vivo efficacy with target engagement. Specific study parameters and results remain client-confidential, but representative outlines and data presentations can be shared on request to illustrate how the model performs across study designs.

Why Choose Alfa Cytology?

An orthotopic gastric model is only as strong as the discipline behind its cell line, surgery, and imaging. Alfa Cytology brings authenticated reagents, refined technique, and integrated analysis together under one preclinical workflow, so MET-driven programs move forward with fewer surprises. Clients typically point to advantages such as:

• Authenticated, low-passage Hs 746T stocks with STR verification and routine mycoplasma screening.
• Established subserosal implantation technique that supports consistent tumor initiation and clean imaging baselines.
• Longitudinal bioluminescence readouts that resolve treatment effects earlier than caliper-based endpoints.
• Flexible host and design options spanning nude, SCID, and NSG recipients with customized dosing schedules.
• Coordinated endpoint analysis combining tumor metrics, metastasis mapping, histopathology, and biomarker work.
• A single accountable study team providing regular updates and clear, decision-focused deliverables.

Contact Us

If your program targets the MET pathway or requires a human gastric cancer orthotopic model with quantitative imaging readouts, contact us to review your study concept. You can also reach out to Alfa Cytology for a tailored proposal covering model setup, imaging cadence, and endpoint analysis — our preclinical team is ready to help you design the right experiment.

For research use only. Not intended for any clinical use.